Recent results from the FLAURA2 and MARIPOSA-2 trials underline the continued role of chemotherapy in the treatment of patients with EGFR-mutated non-small-cell lung cancer in the era of targeted therapies. Herein, we argue that the most appropriate and rational sequence and/or combination of therapies remains a matter of discussion.

中文翻译：

---

EGFR 突变 NSCLC 的化疗：优化 TKI 和阿米万他单抗的组合

FLAURA2 和 MARIPOSA-2 试验的最新结果强调了在靶向治疗时代化疗在治疗 EGFR 突变非小细胞肺癌患者中的持续作用。在此，我们认为最合适和合理的治疗顺序和/或组合仍然是一个讨论问题。